Galmed Pharma (GLMD)
4.63
0.00 (0.00%)
Upcoming Events
Latest Headlines
Galmed Pharma rebrands as Eocene, changes ticker to EOCN
September 9, 2026 7:32 AM - StreetInsider
Form 6-K/A Galmed Pharmaceuticals For: Jul 22
August 19, 2026 4:05 PM - SEC Filing
Form 6-K Galmed Pharmaceuticals For: Aug 19
August 19, 2026 7:05 AM - SEC Filing
Galmed's Colospan reports feasibility data on tissue assessment tool
August 19, 2026 7:01 AM - StreetInsider
Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology
August 19, 2026 7:00 AM - PR NewsWire
Form 6-K Galmed Pharmaceuticals For: Aug 17
August 17, 2026 9:20 AM - SEC Filing
Galmed's Aramchol shows added cell death in prostate cancer study
August 17, 2026 9:15 AM - StreetInsider
Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models
August 17, 2026 9:15 AM - PR NewsWire
Form 6-K Galmed Pharmaceuticals For: Aug 14
August 14, 2026 4:32 PM - SEC Filing
Form 6-K Galmed Pharmaceuticals For: Jul 31
July 31, 2026 4:06 PM - SEC Filing
Form 6-K Galmed Pharmaceuticals For: Jul 29
July 29, 2026 4:05 PM - SEC Filing
Form 6-K Galmed Pharmaceuticals For: Jul 28
July 28, 2026 7:20 AM - SEC Filing
Galmed develops dissolving film form of Aramchol for Parkinson's disease
July 28, 2026 7:01 AM - StreetInsider
Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market
July 28, 2026 7:00 AM - PR NewsWire
Full Article List
